Home/Filings/4/0001610717-23-000277
4//SEC Filing

McClure Matthew W. 4

Accession 0001610717-23-000277

CIK 0001799448other

Filed

Sep 11, 8:00 PM ET

Accepted

Sep 12, 4:08 PM ET

Size

5.4 KB

Accession

0001610717-23-000277

Insider Transaction Report

Form 4
Period: 2023-09-08
McClure Matthew W.
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-09-08+48,00048,000 total
    Exercise: $0.84Exp: 2033-09-08Common Stock (48,000 underlying)
Footnotes (1)
  • [F1]1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Documents

1 file

Issuer

Aligos Therapeutics, Inc.

CIK 0001799448

Entity typeother

Related Parties

1
  • filerCIK 0001927121

Filing Metadata

Form type
4
Filed
Sep 11, 8:00 PM ET
Accepted
Sep 12, 4:08 PM ET
Size
5.4 KB